← All companies

LYEL

Lyell Immunopharma, Inc.

LYEL Nasdaq Pharmaceutical Preparations EDGAR ↗

$12.87

-0.07 -0.54%

Key statistics

from XBRL data in SEC filings

Market cap

$300M

Revenue (TTM)

$31.0K

Net income (TTM)

-$246M

EPS (TTM)

$-13.62

P/E ratio

—

Dividend yield

—

Free cash flow

-$151M

Cash

$90.8M

Total assets

$351M

Gross margin

—

52-week range

$9.28 – $45.00

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Shareholder vote results Jun 15, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release) May 6, 2026 10-K Fiscal year ended 2025-12-31 Mar 12, 2026 8-K Results of operations (earnings release) Mar 12, 2026 8-K Director or officer change Mar 9, 2026 8-K Other events Dec 8, 2025 8-K Amended charter or bylaws Dec 5, 2025 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Nov 10, 2025 8-K Director or officer change Nov 3, 2025 8-K Director or officer change Sep 16, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 8-K Results of operations (earnings release) Aug 12, 2025 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Jul 25, 2025 8-K Unregistered sale of equity Jun 26, 2025 8-K Other events Jun 17, 2025 8-K Director or officer change Jun 9, 2025 8-K Modified rights of security holders May 28, 2025 8-K Shareholder vote results May 21, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 8-K Exit or disposal costs; Director or officer change; Regulation FD disclosure Apr 1, 2025 10-K Fiscal year ended 2024-12-31 Mar 11, 2025 8-K Results of operations (earnings release) Mar 11, 2025 8-K Delisting notice or listing-rule failure Jan 24, 2025 8-K/A Jan 10, 2025 8-K Other events Dec 10, 2024 8-K Director or officer change Nov 26, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Entered a material agreement; Completed an acquisition or disposition; Director or officer change; Regulation FD disclosure Oct 31, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure; Other events Oct 24, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Results of operations (earnings release) Aug 7, 2024 8-K Regulation FD disclosure; Other events Jun 26, 2024 8-K Shareholder vote results Jun 14, 2024 10-Q Quarter ended 2024-03-31 May 6, 2024 8-K Results of operations (earnings release) May 6, 2024